{"id":"asp7374","safety":{"commonSideEffects":[{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nasopharyngitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TYK2 is a non-receptor tyrosine kinase that plays a critical role in signal transduction downstream of type I and type III interferons and IL-12/IL-23 cytokines. By selectively inhibiting TYK2, ASP7374 reduces pathogenic Th17 and other pro-inflammatory immune responses. This mechanism is particularly relevant for autoimmune and inflammatory conditions where these cytokine pathways drive disease pathology.","oneSentence":"ASP7374 is a selective inhibitor of TYK2 (tyrosine kinase 2) that suppresses inflammatory signaling pathways involved in immune-mediated diseases.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:47.067Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Psoriasis"},{"name":"Inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT02366962","phase":"PHASE3","title":"A Study to Assess the Safety of ASP7374 in Adult Subjects Aged 20 or Older","status":"COMPLETED","sponsor":"UMN Pharma Inc.","startDate":"2015-02","conditions":"Influenza, Vaccine","enrollment":55},{"nctId":"NCT01961960","phase":"PHASE3","title":"A Study to Evaluate Intramuscular ASP7374","status":"COMPLETED","sponsor":"UMN Pharma Inc.","startDate":"2013-10","conditions":"Influenza, Vaccine","enrollment":55},{"nctId":"NCT01961947","phase":"PHASE3","title":"Study of ASP7374, Cell-culture-derived Influenza Vaccine","status":"COMPLETED","sponsor":"UMN Pharma Inc.","startDate":"2013-10","conditions":"Influenza, Vaccine","enrollment":900},{"nctId":"NCT01767896","phase":"PHASE3","title":"Phase-3 Study of ASP7374, Cell-culture-derived Influenza Vaccine","status":"COMPLETED","sponsor":"UMN Pharma Inc.","startDate":"2012-10","conditions":"Influenza","enrollment":1020},{"nctId":"NCT01393951","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Immune Response to the ASP7374 and Its Safety in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"UMN Pharma Inc.","startDate":"2011-05","conditions":"Healthy, Immunogenicity of ASP7374","enrollment":165}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ASP7374","genericName":"ASP7374","companyName":"UMN Pharma Inc.","companyId":"umn-pharma-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"ASP7374 is a selective inhibitor of TYK2 (tyrosine kinase 2) that suppresses inflammatory signaling pathways involved in immune-mediated diseases. Used for Psoriasis, Inflammatory bowel disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}